Glaukos (GKOS) Stock Rating Reaffirmed by Stephens
Stephens reaffirmed their buy rating on shares of Glaukos (NYSE:GKOS) in a research report report published on Thursday. They currently have a $36.00 price target on the medical instruments supplier’s stock.
A number of other analysts also recently weighed in on the company. BMO Capital Markets restated an outperform rating and issued a $36.00 target price (down previously from $38.00) on shares of Glaukos in a research report on Thursday. William Blair restated an outperform rating on shares of Glaukos in a research report on Thursday. Canaccord Genuity dropped their target price on Glaukos from $48.00 to $43.00 and set a buy rating for the company in a research report on Thursday. Cantor Fitzgerald set a $43.00 target price on Glaukos and gave the stock a buy rating in a research report on Wednesday, February 28th. Finally, Stifel Nicolaus lowered their price objective on Glaukos from $42.00 to $39.00 and set a buy rating for the company in a research report on Monday, February 26th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $41.25.
Glaukos (NYSE:GKOS) traded up $0.89 during trading hours on Thursday, reaching $33.18. The company had a trading volume of 50,337 shares, compared to its average volume of 508,765. The company has a market cap of $1,121.78, a P/E ratio of -3,225.77 and a beta of 1.07. Glaukos has a one year low of $23.08 and a one year high of $52.48.
Hedge funds have recently made changes to their positions in the business. Ameritas Investment Partners Inc. lifted its position in Glaukos by 93.1% in the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 1,212 shares during the last quarter. Valeo Financial Advisors LLC bought a new stake in Glaukos in the third quarter valued at approximately $111,000. UBS Asset Management Americas Inc. bought a new stake in Glaukos in the second quarter valued at approximately $274,000. Quantbot Technologies LP lifted its position in Glaukos by 291.3% in the third quarter. Quantbot Technologies LP now owns 7,653 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 5,697 shares during the last quarter. Finally, First Republic Investment Management Inc. lifted its position in Glaukos by 47.1% in the third quarter. First Republic Investment Management Inc. now owns 8,300 shares of the medical instruments supplier’s stock valued at $274,000 after purchasing an additional 2,659 shares during the last quarter.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.